{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.183","upperLimit":"1.938","value":"1.87"},{"groupId":"OG001","lowerLimit":"1.906","upperLimit":"2.793","value":"2.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \\>=90% or to \\<200mg/24h. In addition to above, if present at baseline, \\>=50% reduction in the size SPD of STPs was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all randomized population.","reportingStatus":"POSTED","timeFrame":"From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months","title":"Time to First Response (TT1R)","type":"SECONDARY","unitOfMeasure":"months"}